{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007055","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.945281+00:00","generated_at":"2026-06-02T18:13:04.536567+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD","bullets":["Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.","Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.","Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.","Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.","R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007055","json":"https://secwatch.observer/filing/0001558370-24-007055.json","markdown":"https://secwatch.observer/filing/0001558370-24-007055.md","text":"https://secwatch.observer/filing/0001558370-24-007055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/0001558370-24-007055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/acrs-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:13:04.536567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ac64782dd907214dd2a83720be8b6da6cc35579","claim":"Aclaris Therapeutics, Inc. reported first quarter of 2024 results: revenue $2.4 million, net income Net loss was $16.9 million.","evidence_excerpt":"​ Financial Results First Quarter 2024 ● Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023. ● Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/0001558370-24-007055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"Net loss was $16.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}